RxDoctor Payments Data

Wesley Kerr, MD

Epilepsy · Pittsburgh, PANPI 1720506272

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $50,312 of the $54,315 with a category attached, or 92.6%. 7 manufacturers reported payments, led by SK Life Science, Inc. at 43.7% of the total. 2025 is the largest year on record at $23,159, more than ten times the $207 reported in 2021. Among epilepsy clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$54,315in general payments, 2019–2025

Across 69 payments — averaging $787.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • SK Life Science, Inc.$24K
  • Neurelis, Inc.$12K
  • UCB, Inc.$8K
  • UCB SA$4K
  • Jazz Pharmaceuticals Inc.$4K
  • Azurity Pharmaceuticals, Inc.$2K
  • plus $1K from 1 others

What the payments were for

  • Consulting fees$50,31293%
  • Speaking & faculty fees$1,0202%
  • Travel & lodging$1,3322%
  • Food & beverage$1,6523%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$54,315 in reported general payments places this provider in the 95th percentile of 28 epilepsy providers in Pennsylvania.

See all epilepsy providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$7,821
Medicare patients
82
Services billed
104

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lacosamide14$1,760
Oxcarbazepine13$466
Lamotrigine28$347
Levetiracetam16$314

Paid to pharmacies, not to this prescriber.

Other epilepsy in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →